Results of a prospective phase 2 pilot trial of 177Lu–PSMA-617 therapy for metastatic castration-resistant prostate cancer including imaging predictors of treatment response and patterns of progression - Emmett, L; Crumbaker, M; Ho, B (Clinical genitourinary cancer, 2019)